Your questions - our approach

Dermal drug testing

In what concentration does a dermal drug reach the dermis?

We provide a cross-sectional profile of your dermal drug in all skin layers by

  • applying a formulated drug via the intended route (e.g. topical, subcutaneous, intravenous, oral)
  • using specialized in-vivo/ex-vivo skin biopsies
  • slicing the biopsies parallel to the skin surface
  • analyzing the drug concentration separately in each slice

We investigate the continuous pharmacokinetic profile in the skin by

  • continuously sampling dermal interstitial fluid
  • quantifying drug concentrations in the dermal interstitial fluid samples.

Which biochemical effects are caused by the dermal drug?

We investigate potential effects and any side effects of your drugs directly in the skin by

  • applying a formulated drug via the intended route (e.g. subcutaneous, intravenous, oral, topical)
  • placing OFM or microdialysis probes in the dermis
  • continuously sampling dermal interstitial fluid
  • analyzing a wide PD marker panel in the dermal interstitial fluid samples for a continuous PD profile of the drug.

 

Benefits

Your Benefits

  • Spatial and temporal pharmacokinetic profiles for your drug in the dermis.
  • Receive a highly resolved time profile in a preclinical or clinical set-up for up to 36 hours.
  • Reduce the risk of failure by access to in-vivo PK/PD data at the earliest possible stage in drug development.
  • Reduce your time and costs by reducing risk of failure in drug development.
  • Identical trial set-up in preclinical, ex-vivo and clinical experiments.
  • At the earliest possible stage in drug development you can demonstrate intended mechanisms of action and possible side effects for your drug directly in the dermis.
    Contact
    Download

    Download the current folder on our dermal PK/PD services here.